Eprosartan mesylate
Modify Date: 2024-01-04 19:31:26
Eprosartan mesylate structure
|
Common Name | Eprosartan mesylate | ||
|---|---|---|---|---|
| CAS Number | 144143-96-4 | Molecular Weight | 520.618 | |
| Density | 1.26 g/cm3 | Boiling Point | 660.6ºC | |
| Molecular Formula | C24H28N2O7S2 | Melting Point | 248 °C | |
| MSDS | Chinese USA | Flash Point | 353.3ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of Eprosartan mesylateEprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively. IC50 Value: 9.2 nM(in rat adrenal cortical membranes); 3.9 nM(in human adrenal cortical membranes)Target: Angiotensin Receptor Type-1(AT1)in vitro: Eprosartan mesylate, is one of the highly selective, orally active, non-peptide angiotensin-II-receptor antagonists [1]. In rat and human adrenal cortical membranes, Eprosartan displaced specifically bound [125I]AII with IC50 of 9.2 and 3.9 nM, respectively. Eprosartan also inhibited [125I]AII binding to human liver membranes (IC50 = 1.7 nM) and to rat mesenteric artery membranes (IC50 = 1.5 nM). In rabbit aortic smooth muscle cells, Eprosartan caused a concentration-dependent inhibition of AII-induced increases in intracellular Ca++ levels. In rabbit aortic rings [2].in vivo: Administration of Eprosartan (3-10 mg/kg) intraduodenally or intragastrically to conscious normotensive rats resulted in a dose-dependent inhibition of the pressor response to AII (250 ng/kg, i.v.). At 10 mg/kg, i.d., significant inhibition of the pressor response to AII was observed for 3 hr. In this same rat model, Eprosartan had no effect on base-line pressure or on the pressor response to norepinephrine or vasopressin [2]. Eprosartan is highly effective and safe in lowering blood pressure, notably SBP, in older subjects with mild to moderate hypertension [3]. Treatment with eprosartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated, with dizziness and asthenia being the most common side effects [4]. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed [5]. |
| Name | eprosartan methanesulfonate |
|---|---|
| Synonym | More Synonyms |
| Description | Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively. IC50 Value: 9.2 nM(in rat adrenal cortical membranes); 3.9 nM(in human adrenal cortical membranes)Target: Angiotensin Receptor Type-1(AT1)in vitro: Eprosartan mesylate, is one of the highly selective, orally active, non-peptide angiotensin-II-receptor antagonists [1]. In rat and human adrenal cortical membranes, Eprosartan displaced specifically bound [125I]AII with IC50 of 9.2 and 3.9 nM, respectively. Eprosartan also inhibited [125I]AII binding to human liver membranes (IC50 = 1.7 nM) and to rat mesenteric artery membranes (IC50 = 1.5 nM). In rabbit aortic smooth muscle cells, Eprosartan caused a concentration-dependent inhibition of AII-induced increases in intracellular Ca++ levels. In rabbit aortic rings [2].in vivo: Administration of Eprosartan (3-10 mg/kg) intraduodenally or intragastrically to conscious normotensive rats resulted in a dose-dependent inhibition of the pressor response to AII (250 ng/kg, i.v.). At 10 mg/kg, i.d., significant inhibition of the pressor response to AII was observed for 3 hr. In this same rat model, Eprosartan had no effect on base-line pressure or on the pressor response to norepinephrine or vasopressin [2]. Eprosartan is highly effective and safe in lowering blood pressure, notably SBP, in older subjects with mild to moderate hypertension [3]. Treatment with eprosartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated, with dizziness and asthenia being the most common side effects [4]. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed [5]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.26 g/cm3 |
|---|---|
| Boiling Point | 660.6ºC |
| Melting Point | 248 °C |
| Molecular Formula | C24H28N2O7S2 |
| Molecular Weight | 520.618 |
| Flash Point | 353.3ºC |
| Exact Mass | 520.133789 |
| PSA | 183.41000 |
| LogP | 5.32920 |
| Vapour Pressure | 2.37E-18mmHg at 25°C |
| Storage condition | room temp |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.
BMC Immunol. 10 , 52, (2009) Growing knowledge about cellular interactions in the immune system, including the central role of cytokine networks, has lead to new treatments using monoclonal antibodies that block specific componen... |
| 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid,methanesulfonic acid |
| 4-({2-Butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzolcarbonsäure-methansulfonsäure(1:1) |
| acide 4-({2-butyl-5-[(1E)-2-carboxy-3-thiophén-2-ylprop-1-én-1-yl]-1H-imidazol-1-yl}méthyl)benzoïque - acide méthanesulfonique (1:1) |
| MFCD08141807 |
| 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αE)-, methanesulfonate (1:1) |
| Eprosartan mesylate |
| 4-({2-butyl-5-[(1E)-2-carboxy-3-thiophen-2-ylprop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate |
| 2-Thiophenepropanoic acid, α-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (αZ)-, methanesulfonate (1:1) |
| Eprosartan Monomethanesulfonate SKF-108566J Teveten |
| 4-({2-Butyl-5-[(1Z)-2-carboxy-3-(2-thienyl)-1-propen-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1) |
| 4-({2-Butyl-5-[(1E)-2-carboxy-3-(2-thienyl)-1-propen-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1) |
| 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid methanesulfonate (1:1) |
| Eprosartan (mesylate) |
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Eprosartan mesylate
- Price: ￥698.0/50mg ￥2068.0/250mg
- Purity: 99.0%
- Stocking Period: Inquiry
- Contact: Liu jia
- DC Chemicals Limited
- China
- Product Name: Eprosartan mesylate
- Price: $300.0/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Dayang Chem (Hangzhou) Co., Ltd.
- China
- Product Name: Eprosartan mesylate
- Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
- Purity: 98.0%
- Stocking Period: Inquiry
- Contact: Ms Wang
- Henan Tianfu Chemical Co., Ltd.
- China
- Product Name: Eprosartan mesylate
- Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
- Purity: 99.0%
- Stocking Period: Inquiry
- Contact: Anson
Get all suppliers and price by the below link:
Price: $66/10mM*1mLinDMSO
Reference only. check more Eprosartan mesylate price